Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas

NCT02215447 is registered in ClinicalTrials.gov with Barwon Health as lead sponsor.

NCT NCT02215447
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02215447 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas
Lead sponsor
Barwon Health
Phase
Phase 2
Overall status
Unknown status
Start date
May 31, 2015
Completion date
October 31, 2020
Enrollment
4 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal neuroendocrine carcinomas